Clinical medicine future perspective

More and more clinical trials in children are taking place and are improving the availability of ready-made specific paediatric drug delivery systems. Moreover, from the perspective of the new European Union regulations on medicines for children (European Commission, 2006), the number of trials will increase in the future. Meanwhile, extemporaneous dispensing, even though it should remain the last resort, is still an important activity for paediatric pharmacists and carers (Yeung et al., 2004). 

Here we review current knowledge on the enzymes and related binding proteins that are involved in covalent modifications to histones. We begin with a brief overview of the field aimed at the non-expert, then focus on the covalent modifications themselves as catalysed by specific enzymes. We also focus on the consequences of these modifications for binding interactions with other proteins that modulate gene expression. The field is one that is rapidly evolving and we hope to convey some of the excitement that we feel about recent discoveries in histone science, particularly from a molecular perspective. Two inhibitors of histone modifying enzymes are in clinical use, with more likely to be introduced in the near future. Thus, the development of modifiers of histone biochemistry is of medicinal as well as basic interest. 

Kwnica-Worms D. Perspectives in imaging present and future prospects of clinical molecular imaging. In Kufe D, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine. Hamilton, Ontario BC Decker, Inc., 2003 2764-2769. 

---